CPHL FY26 profit softens 11%

According to Mettis Global, Citi Pharma Limited (CPHL) posted a consolidated net profit of Rs790.33m for the fiscal year ended June 30, 2026, which is 11% lower than the Rs892.04m earned a year earlier. Earnings per share fell to Rs3.46 from Rs3.90 in FY25, on both a basic and diluted basis. The decline came despite 7% revenue growth, and the report identified higher marketing overheads, elevated financing charges and rising operating expenses as the main pressures on final earnings.

Consolidated net sales grew 7% to Rs14.08bn, while cost of sales rose 4% to Rs11.60bn, lifting gross profit 23% to Rs2.47bn. Administrative and general expenses increased 15% to Rs254.51m, and marketing and distribution costs jumped 45% to Rs278.04m. As a result, operating profit rose 21% to Rs1.94bn.

Financial charges climbed 18% to Rs388.77m and other operating expenses reached Rs299.03m, while other income more than doubled to Rs91.93m. Profit before taxation eased slightly to Rs1.34bn, and a corporate tax charge of Rs554.18m, up 20%, reduced the bottom line to Rs790.33m.